ACUTE MYELOID LEUKEMIA; DEMOGRAPHIC FEATURES AND FREQUENCY OF VARIOUS SUBTYPES IN ADULT AGE GROUP

Infant acute myeloid leukemia (AML) is a rare subgroup of AML of children <2 years of age. It is as frequent as infant acute lymphoblastic leukemia (ALL) but not clearly distinguished by study groups. However, infant AML demonstrates peculiar clinical and biological characteristics, and its prognosis differs from AML in older children. Acute megakaryoblastic leukemia (AMKL) is very frequent in this age group and has raised growing interest. Thus, AMKL is a dominant topic in this review. Recent genomic sequencing has contributed to our understanding of infant AML. These data demonstrated striking features of infant AML: fusion genes are able to induce AML transformation without additional cooperation, and unlike AML in older age groups there is a paucity of associated mutations. Mice modeling of these fusions showed the essential role of ontogeny in the infant leukemia phenotype compared to older children and adults. Understanding leukemogenesis may help in developing new targeted treatments to improve outcomes that are often very poor in this age group. A specific diagnostic and therapeutic approach for this age group should be investigated.

Download Full-text

An Analysis of Treatment Choices for Acute Myeloid Leukemia in Patients 60 Years and Older from the University of Duesseldorf AML/MDS Database.

Blood ◽

10.1182/blood.v110.11.4378.4378 ◽

2007 ◽

Vol 110 (11) ◽

pp. 4378-4378

Author(s):

Viola Klaerner ◽

Andrea Kuendgen ◽

Peter De Porre ◽

Barbara Hildebrandt ◽

Rainer Haas ◽

...

Keyword(s):

Overall Survival ◽

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Median Overall Survival ◽

Treatment Choice ◽

Age Group ◽

Treatment Choices ◽

History Of ◽

Blast Count ◽

Acute Myeloid

Abstract Treatment choices for elderly patients (pts) with acute myeloid leukemia (AML) were assessed through a retrospective analysis of 705 pts aged ≥ 60 years (yrs), diagnosed between January 1986 and December 2005. The treatments administered to pts were grouped into three categories: best supportive care (BSC), combination induction chemotherapies including high dose ara-C (HDT), and low-intensity single-agent therapies (LDT; approx. 50% were low-dose ara-C, others included valproic acid, thalidomide, lenalidomide, decitabine, 5-azacytadine, gemcitabine and etoposide). The reviewed AML population consisted of 57% of pts aged 60–69 yrs, 17% 70–74 yrs and 26% ≥75 yrs; median age at baseline was 70 yrs. Overall, 41% of pts had antecedent MDS, and 75% had a bone marrow (BM) blast count of 20–30% at baseline. Of the 705 pts 56.5% who received BSC, 33.2% were treated with HDT and 10.4% with LDT. Age was shown to strongly influence the choice of treatment. The use of HDT dropped significantly from 57.6% for pts <65 yrs old to 24.2% for patient 70 to 74 yrs. At ≥75 yrs, 89.2% of the pts received BSC, only 4.3% received HDT, and 6.5% received LDT. Antecedent MDS was another important factor influencing treatment choices. In the age group 60 to 69 yrs, HDT treatments dropped from 67.1% in pts with no prior history of MDS to 28.9% in pts with a history of MDS. For pts ≥70 yrs, there was a clear drop in administration of HDT from 21.8% to 2.1% respectively. A third factor impacting on treatment choice was BM blast percentage. The majority of pts with a baseline BM blast count of over 30% were treated with HDT regardless of age, but the proportion decreased from 86.4% in pts <70 yrs of age to 54.2% in the age group ≥70 yrs, with a corresponding increase in BSC treatment. In contrast, 84.2% of pts 70 yrs and older with a blast count of 20–30% were treated with BSC. An unfavorable karyotype is also considered to be an adverse prognostic variable. However, karyotype exhibited an influence on treatment choice only in the group of pts 70 yrs and older, where 41.3% of pts with not unfavourable karyotype vs 19.6% with unfavourable karyotype received intensive chemotherapy. The median overall survival based upon treatment type, age or prior MDS shows that pts receiving either HDT(<70 yrs 9.93 month (mth); ≥70 yrs 7.9 mth; prior MDS 5.54 mth) or LDT (<70 yrs 10.62 mth; ≥70 yrs 6.39 mth; prior MDS 6.1 mth) survived significantly longer than those treated with BSC only (<70 yrs 4.03 mth; ≥70 yrs 2.56 mth; prior MDS 1.21 mth). Interestingly the analysis showed not much difference in median overall survival for pts treated with HDT (9.67 mth) vs LDT (9.54 mth). However, the number of pts for LDT is too small to make statistically relevant conclusions. One reason for the extremely poor outcome in pts treated with BSC might be a worse performance status compared with pts treated with chemotherapies. In summary, treatment choices are affected by age, BM blast count and a history of prior MDS. In the future, according to newer data from several groups, karyotype will presumably gain more importance for the selection of treatment. The analysis indicated that BSC was a major treatment option for elderly AML pts. However results show very poor overall survival for untreated AML pts, justifying the use of new agents to improve outcome in this subgroup.

Download Full-text

Temporal Trends in the Proportion Cured Among Patients Diagnosed with Acute Myeloid Leukemia in Sweden 1973-2001, a Population-Based Study.

Blood ◽

10.1182/blood.v114.22.1378.1378 ◽

2009 ◽

Vol 114 (22) ◽

pp. 1378-1378

Author(s):

Åsa Rangert Derolf ◽

Therese M-L Andersson ◽

Paul C Lambert ◽

Sigurdur Y Kristinsson ◽

Sandra Eloranta ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Patient Survival ◽

Age Groups ◽

Population Based ◽

Age Group ◽

Survival Times ◽

Population Based Study ◽

Cure Fraction ◽

Acute Myeloid

Abstract Abstract 1378 Poster Board I-400 Background: Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and is rapidly fatal without specific therapy. In a recently published population-based study we showed large differences in 1- and 5-year relative survival in AML patients in Sweden depending on age at diagnosis and year of diagnosis[1]. Here we use an alternative approach to study patient survival that simultaneously estimates the proportion of patients cured from AML and the survival time of those patients that are not cured. The cure proportion provides a better estimate of long-term survival than 5-year survival and is therefore of direct interest to patients and health care professions. Methods: We conducted a population-based cohort study including 6,439 patients aged 19-79 diagnosed with AML in Sweden 1973 to 2001. Patients are considered statistically cured when, as a group, their mortality returns the level of a comparable general population. We estimated mixture cure fraction models that provide estimates of both the cure proportion and the distribution of survival times of the “uncured”. Age at diagnosis was classified into four categories 19-40, 41-60, 61-70 and 71-80 and year of diagnosis was modeled using restricted cubic splines. Results: During the first years of the study period the cure fraction was less than 5% for all age groups and the median survival time for “uncured” approximately 0.5 years or less. In 2000 the estimated cure proportion was 68% (95% CI 56%-77%) for the youngest age group, 32% (25-39%) for those aged 41-60, 8.4% (3.1-21%) for those aged 61-70 at diagnosis and 4.3% (2.3-8.1%) for the oldest age group. The estimated median survival times for “uncured” were 0.74 (0.43-1.26), 0.71 (0.53-0.97), 0.69 (0.51-0.95) and 0.37 (0.31-0.44) years respectively (Table 1). The improvement in survival manifested as longer survival among the uncured during the early calendar years but increases in the cure proportion were observed during later years. Conclusion: There are large differences in the proportion cured between the age groups. In younger patients the cure proportion has increased dramatically, while survival of the “uncured” actually decreased in the last time period. In the older age groups improvement is merely seen within the survival of the “uncured”. [1] Derolf AR, Kristinsson SY, Andersson TM-L, Landgren O, Dickman PW, Björkholm M. Improved patient survival for acute myeloid leukemia: A population-based study of 9,729 patients diagnosed in Sweden 1973-2005. Blood. 2009 Apr 16;113(16):3666-72. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

A national study of allogeneic stem cell transplantation for adults with acute myeloid leukemia: Do gender and age above 70 years matter?

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e19020 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e19020-e19020

Author(s):

Josephine Emole ◽

Leyla Shune ◽

Oleksandra Lupak ◽

Ajoy Lawrence Dias

Keyword(s):

Acute Myeloid Leukemia ◽

Stem Cell ◽

Stem Cell Transplantation ◽

Hospital Mortality ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Myeloid Leukemia ◽

Age Groups ◽

Age Group ◽

Acute Myeloid

e19020 Background: Allogeneic stem cell transplantation (alloSCT) is increasingly being offered to older patients with acute myeloid leukemia (AML) due to availability of reduced-intensity conditioning regimens and better supportive care. Though studies have shown improving alloSCT survival outcomes in older age groups, it is still not known if older age confers higher mortality and morbidity during transplant hospitalization. We queried a national inpatient database to evaluate in-hospital mortality and resource utilization during alloSCT for AML in patients >70 years compared to a younger age group. Methods: We conducted a retrospective study of alloSCT for AML patients ≥ 18 years using the 2018 National Inpatient Sample database. Hospitalizations were selected using International Classification of Disease, tenth revision (ICD-10) codes. Demographics, comorbidities, transplant, and outcome variables were compared between a reference age group (18-70 years) and a comparator group (> 70 years). Study outcomes were in-hospital mortality, length of stay (LOS) and transplant complications. Regression models were fit to assess the association between predictors and outcomes. Results: During the study period, 2610 alloSCT met the inclusion criteria. This cohort consisted of 50% males and 77% Caucasians. Only 7% of these alloSCT were performed for patients > 70 years. Patients >70 yrs had a lower proportion of females compared to the reference age group (32% versus 52%, p<0.01). There were no significant differences in racial distribution, Charlson comorbidity index or median income between the 2 age groups. In-hospital mortality rates for the reference age group versus >70 years were 3% and 5% respectively (p=0.35). In a multivariable model, we found no association between age >70 years and in-hospital transplant mortality. Acute graft versus host disease was more frequent among the reference age group (14% versus 2%, p=0.04), but there were no differences in LOS or rates of graft failure, respiratory failure, sepsis, and acute renal failure between the 2 groups. Conclusions: Despite similar in-hospital transplant outcomes as their younger counterparts, patients >70 years comprised only a small proportion of alloSCT performed for AML in our study. Females were more disproportionately affected by this age disparity. More studies are necessary to identify barriers to alloSCT for older AML patients, more so for older females.

Download Full-text

Acute Myeloid Leukemia (AML) Hospitalizations: Racial Disparity in Outcomes of Patients with Comorbidities

Blood ◽

10.1182/blood-2021-153029 ◽

2021 ◽

Vol 138 (Supplement 1) ◽

pp. 4135-4135

Author(s):

Sara Taveras Alam ◽

Deepa Dongarwar ◽

Elyse Lopez ◽

Sarvari Venkata Yellapragada ◽

Gustavo Rivero ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Research Funding ◽

Hospital Death ◽

Age Group ◽

Hispanic Patients ◽

Comorbidity Index ◽

Race Ethnicity ◽

Primary Payer ◽

Acute Myeloid

Abstract Background: Acute Myeloid Leukemia (AML) outcomes are dependent on leukemia-specific factors, such as cytogenetics and patient-specific factors, such as age and performance status. Racial and socioeconomic disparities have become apparent with self-reported African American race associated with poor survival in AML pts < 60 years (y) of age. We analyzed in-hospital death among AML-related hospitalizations and evaluated differences in sociodemographic characteristics, focusing on the effect of age and race. Methods: We conducted a retrospective cohort study using the Nationwide Inpatient Sample (HCUP-NIS), the largest all-payer database of hospital admissions in the United States, from January 1 st, 2009 through December 31 st, 2018. The study sample consisted of AML-associated hospitalizations of patients aged 18 years of age and older, identified on the basis of the presence of any ICD-9 and 10 codes indicative of AML We categorized patients' ages in groups of <60 y and ≥ 60 y. Ethnicity was initially stratified by reported ethnicity (Hispanic, Non-Hispanic), and the Non-Hispanic group was subdivided into White, Black, or other. The primary payer for the hospitalization was classified. As a proxy for socioeconomic status, the HCUP-NIS provides zip-code-level estimates of median household income, grouped into quartiles based on the patient's residence. Hospital factors included census region, bed size, and hospital type. Patients' comorbidity status was captured using Elixhauser Comorbidity Index (0, 1-4, 5+). Outcome of interest was in-hospital death. Among different age groups and ethnic groups of patients with AML, we used survey logistic regression to generate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) that measured the independent associations between various patient hospitalization characteristics and inpatient death. We adopted a 5% type I error rate for the calculation of CIs, and used appropriate survey weighting to generate national prevalence estimates considering the complex sampling design of the NIS. Statistical analyses were performed using R (version 3∙6∙1) and RStudio (Version 1∙2∙5001). Results: Of 662,417 AML-related hospitalizations, 57.6% were in patients ≥60 y. Of AML-related hospitalizations in patients <60 y, 61.6% were in NH-White patients, 11.2% were in NH Blacks, and 11.7% were in Hispanics. Of AML-related hospitalizations in patients ≥60 y, 74.6% were in NH-Whites, 7.3% in NH-Blacks and 5.4% in Hispanics. Analysis of in-hospital death among AML-related hospitalizations, stratified by race/ethnicity revealed increased in-hospital death among male NH-Black AML patients ≥ 60 y as compared to NH-Black females in the same age group (OR 1.24; CI 1.04-1.47) and an increased in-hospital death among Hispanic patients ≥ 60 years with comorbidities relative to their counterparts in the same age group without comorbidities (OR 17.8; CI 11.32-29.37 for Elixhauser Comorbidity Index 1-4 and OR 2.69; CI 1.09-5.26 for Elixhauser Comorbidity Index ≥5). Differences in income, primary payer, hospital region, size, location or teaching status were not associated with in-hospital death among AML patients stratified by race/ethnicity. See Table 1. Conclusions: We found a significant increase in in-hospital death among Hispanic patients ≥ 60 y with comorbidities relative to their counterparts in the same age group without comorbidities. Yet, comorbidities did not appear to have a statistically significant impact in mortality for patients of other race/ethnicity or those <60 y. It is plausible that the relationship between comorbidities and re-hospitalizations might be impacting our data. Previous work not specific to acute myeloid leukemia has shown that higher comorbidity is associated with an increased risk of readmission. Since our data was based on AML-related hospitalizations rather than patients with AML, it is possible that we are dealing with a false negative error because of patients with comorbidities being readmitted more. The lack of cytogenetic data in NIS is another notable limitation to our work. Nonetheless, we have found striking differences in the outcomes of elderly Hispanic comorbid patients and further evaluations are needed for correlation and to identify areas of optimization in their care. Figure 1 Figure 1. Disclosures Mims: Incyte: Research Funding; AVEO: Research Funding; Pfizer: Research Funding; IDEC: Current holder of individual stocks in a privately-held company; Celgene: Research Funding; Biogen: Current holder of individual stocks in a privately-held company.

Download Full-text

Comparison of Complications Related to Peripherally Inserted Central Catheters, Infusion Ports, and Hickman Catheters in Acute Myeloid Leukemia Patients

Blood ◽

10.1182/blood.v120.21.4288.4288 ◽

2012 ◽

Vol 120 (21) ◽

pp. 4288-4288

Author(s):

Mohammad O. Khalil ◽

Namali Pierson ◽

Hossein Maymani ◽

Jennifer L. Holter ◽

Mohamad Ali Cherry

Keyword(s):

Acute Myeloid Leukemia ◽

Platelet Count ◽

Myeloid Leukemia ◽

Blood Stream Infection ◽

Blood Stream ◽

Cell Transplant ◽

Age Group ◽

Different Types ◽

Oklahoma Health ◽

Acute Myeloid

Abstract Abstract 4288 Background: Intravenous catheters are widely used in acute myeloid leukemia (AML) patients. Complications associated with these catheters are frequently encountered and contribute to morbidity, mortality, and increased cost of treatment. Studies exploring and comparing complications in the different types of catheters in this unique patient population are lacking. We retrospectively studied infectious and thrombotic catheter-related complications in AML patients treated at the largest tertiary referral center for AML in Oklahoma. Methods: AML patients above the age of 18 who were referred to The University of Oklahoma Health Sciences Center from January, 2000 to June, 2012 were identified and medical records were reviewed. Patients were stratified according to type of first catheter inserted (peripherally inserted central catheter (PICC), infusion port (IP), or Hickman). First catheter-related blood stream infection and deep venous thrombosis (DVT) events were reported (subsequent catheter-related complications were not included). Statistical analysis was performed using SAS 9.2 software (SAS Institute Inc). Fisher exact test was used to compare patients with different types of catheters. Results: 195 patients with AML were identified; of which 125 were included in the analysis (Patients referred for stem cell transplant (SCT) were excluded if not treated with prior chemotherapy at our institution). Median age at diagnosis was 51 years. 87 (70%) were males and 38 (30%) were females. 97 (78%) were White, 11 (9%) Native Americans, and 10 (8%) African Americans. 73 (58%) had PICC, 34 (27%) had Hickman, and 17 (14%) had IP. Blood stream infection occurred in 34% of all patients. Blood stream infection rates in each group were 32% in patients with PICC, 47% with IP, and 31% with Hickman (p=0.47). When divided by age group, infections occurred in 41% of patients 55 years of age or older and in 29% of those <55 years (p=0.19). Gram-positive cocci accounted for 57% and Gram-negative rods for 30% of all infections. DVT occurred in 14% of all cases. DVT rates in each group were 22% in patients with PICC, 6% with IP, and none with Hickman (p=0.002). When divided by age group, thrombosis rates were 9% in patients 55 years of age or older and 17% in those <55 years (p=0.29). 39% of patients with platelet count >20,000/microL at the time of event had DVT compared to only 8% of those with platelet count <20,000/microL (p=0.0005). Conclusion: Among AML patients referred to our institution, PICCs were associated with significantly higher rate of DVT compared to IPs and Hickmans. Platelet count >20,000/microL was also associated with significantly higher rate of thrombosis. There was no difference in blood stream infections across the different catheter types. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106

Blood ◽

10.1182/blood.v126.23.2576.2576 ◽

2015 ◽

Vol 126 (23) ◽

pp. 2576-2576

Author(s):

Fabiana Ostronoff ◽

Todd A. Alonzo ◽

Megan Othus ◽

Matthew A. Kutny ◽

Robert B. Gerbing ◽

...

Keyword(s):

Older Adults ◽

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Research Funding ◽

Somatic Mutations ◽

Disease Risk ◽

Age Groups ◽

Therapeutic Strategies ◽

Age Group ◽

Acute Myeloid

Abstract Acute myeloid leukemia (AML) is a genetically heterogeneous and highly resistant hematopoietic malignancy. Despite survival gains over the past several decades, adolescent and young adult (AYA) with AML demonstrate a consistent survival disadvantage as compared to younger patients (age < 15 years). This discrepancy in outcome is likely due to distinct aspects of disease biology in this patient population. In recent years several somatic mutations with biological, prognostic and therapeutic significance have been identified in patients with AML. Nonetheless, these studies have been conducted in pediatric and older adult patients only. Therefore, the prevalence of these somatic mutations remains largely unknown in AYA patients. Herein, we investigate the prevalence of common AML-associated mutations in AYA, here defined as age 15 to 39 years, aiming to characterize the disease and identify mutations that are relevant for therapeutic strategy in this age group. We compare the distribution of these mutations in the 3 age groups: children (age< 15 years), AYA (age 15 to 39 years) and older adults (age> 39 years). Patients enrolled in the COG trials AAML03P1 and AAML0531 and in the SWOG trial S0106 were eligible for this study. Acute promyelocytic leukemia patients were excluded. AAML03P1 enrolled patients 0 to 21 years, AAML0531 enrolled patients 0 to 30 years and S0106 enrolled patients 18 to 60 years of age. We analyzed 1722 patients (age range 0 to 60 years) with newly diagnosed AML. Pre-treatment samples were obtained from AAML03P1 and AAML531 (N=1361) and S0106 (N=361). Mutation analyses were performed by a combination of targeted capture and fragment length analysis. Chi-square test was used to compare variables. The prevalence of each mutation according to age groups is shown on Table 1. Similarly to what is observed in children and older adults, NPM1 and FLT3- ITD are the two most common mutations in AYA patients with a prevalence of 19% and 14%, respectively. When compared to the other age groups, we observe a significant increase in prevalence of both FLT3- ITD and NPM1 with aging, with a significant higher prevalence of these mutations in older adults as compared to AYA and children. Previous studies have shown that mutations in epigenetic modifier genes are enriched in adults with AML as compared to pediatric patients. We evaluated the prevalence of mutations in these genes in the 3 age groups. We observed a significant increase in prevalence in mutations in all epigenetic modifiers genes with aging (Table 1). The combined prevalence of mutation in these genes (IDH1, IDH2, DNMT3A, ASXL1 and IDH1/2) in children, AYA and older adults were 9%, 19% and 39% (P< 0.0001), respectively, highlighting the clinical and biological importance of this class of genes in older patients. In this large collaborative study, we define for the first time the prevalence of common mutations in AYA with AML. Our study shows that the genomic make up of patients with AYA are different from children and older adults, suggesting unique biology of the disease in this age group. Our data raise questions about future therapeutic strategies, which should take into account the age distribution of these genetic lesions. Finally, clinical correlations to determine the prognostic significance of these mutations in AYA are underway and should provide a framework for future disease risk stratification in this age group. In summary, our data shows the distinct genomic profiling of common mutations in AYA, arguing for age specific disease risk stratification as well as therapeutic strategies in this age group. Table 1. Prevalence of common mutations in children, adolescents and young adults (AYA) and older adults with AML Children (<15 years) AYA (15-39 years) Older adults (>40 years) P value FLT3-ITD 13% 19% 23% 0.0006 NPM1 6% 14% 32% < 0.00001 CEBPA 5% 8% 3% 0.02 WT1 6% 9% 5% 0.154 IDH1/2 3% 7% 17% < 0.00001 DNMT3A 0% 2% 16% < 0.00001 ASXL1 2% 4% 7% 0.007 TET2 4% 7% 11% 0.002 Disclosures Radich: Novartis: Consultancy, Research Funding; Incyte: Consultancy; Gilliad: Consultancy; Ariad: Consultancy. Erba:GlycoMimetics; Janssen: Other: Data Safety & Monitoring Committees; Sunesis; Pfizer; Daiichi Sankyo; Ariad: Consultancy; Millennium/Takeda; Celator; Astellas: Research Funding; Seattle Genetics; Amgen: Consultancy, Research Funding; Novartis; Incyte; Celgene: Consultancy, Patents & Royalties.

Download Full-text

ACUTE MYELOID LEUKEMIA;

The Professional Medical Journal ◽

10.29309/tpmj/2017.24.09.820 ◽

2017 ◽

Vol 24 (09) ◽

pp. 1302-1305

Author(s):

Romaisa Naeem ◽

Samina Naeem ◽

Ammarah Sharif ◽

Humera Rafique ◽

Asif Naveed

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Western World ◽

Cross Sectional Survey ◽

Cross Sectional ◽

Adult Age ◽

Male Predominance ◽

Study Results ◽

Medical University ◽

Acute Myeloid

Background: Acute myeloid leukemia (AML) is an aggressive haematologicalmalignancy with highest incidence in older adults. AML accounts for approximately 25% of allleukemias in adults in the Western world, and therefore is the most frequent form of leukemia.Objective: The aim of study was to analyze the demographic and clinical features and frequencyof various subtypes of acute myeloid leukemia in adult age group in our population. Studydesign: Descriptive Cross sectional survey. Settings: The study was conducted in PathologyDepartment, King Edward Medical University, Lahore. Study Period: Five years September2007 to September 2011. Material and Methods: A five year data of patients diagnosed asacute myeloid leukemia was collected from September 2007 to September 2011 in PathologyDepartment, King Edward Medical University, Lahore. Patients on chemotherapy andradiotherapy were excluded from the study. Results: Among the 77 patients of Acute MyeloidLeukemia, Acute myeloid leukemia with maturation AML M2 (37.7%) was the most commonsubtype and the least common was Acute megakaryoblastic leukemia AML M7 (1.3%).Meanage for AML was 28 years (Range 15-75 years). M:F ratio was 1.5:1. Fever was found be the mostfrequent presenting feature followed by pallor, bleeding and gum hypertrophy in the descendingorder. More than 50% patients presented with hepatosplenomegaly. Lymphadenopathy wasseen in 30% of patients. Mean peripheral blood blast count was 29%. 12 patients (15.5%)presented with pancytopenia. Conclusion: The study showed male predominance in Acutemyeloid leukemia with mean age of 28 years and the most common subtype was AML- M2.

Download Full-text